Search Site | Index

About Lymphoma | Advocacy | Art | CAM | Clinical trials 
Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms |
Tests | Treatments | Types of Lymphoma | How to Help

Find Clinical Trial

 by Agent

by Type of Lymphoma & Treatment Status  

Trials of Interest

New trials since October 2018

Phase I since 2017  | Phase III since 2008

Guidelines at Diagnosis | About Clinical Trials

evidence-based support and information


Agents that Target Disease Pathways >  Antibody-Drug Conjugates 

Last update: 12/06/2017

| In the News  | Clinical Trials | Adcetris

An antibody-drug conjugate is a man-made monoclonal antibody* with a toxin linked to it.  In this way the antibody becomes a way to deliver the toxin in a more targeted way - only to cells to which the antibody sticks - in order to increase its efficacy and reduce the risk. 

* What is an antibody (or mono-clonal antibody)? 

When your body detects something that does not belong, such as bacteria, one way it eliminates the threat is to produce antibodies that bind to the protein shapes that are unique to the pathogen.  

See for a video explanation by Roche:

Brentuximab vedotin (below) is the most well known of this class of agents,
but other antibody-drug conjugates are in clinical phase testing.   

Antibody-drug conjugates in clinical phase testing   

ADCT-301 A Novel Antibody-drug Conjugate Against Lymphomas Moves Into Phase I Clinical Trial ADC Review
anti-CD19 + toxin
Find trials | Reports
anti-CD19 + maytansinoi 
Find trials | Reports
anti-CD19 & 22 antibody + immunotoxin
Find trials | Reports
Inotuzumab Ozogamicin
anti-CD22 + calicheamicin 
Find trials | Reports
anti-CD22, conjugated to MMAE
Find trials  | Reports
LMB-2 immunotoxin
anti-CD25 antibody + immunotoxin 
Find trials | Reports
(SGN-35 / brentuximab vedotin) 

+ antitubulin
Find trials  |  Reports

In the News and New Resources

* Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies 
* Technical but readable background on this technology

ADCT-301 A Novel Antibody-drug Conjugate Against Lymphomas Moves Into Phase I Clinical Trial ADC Review
* Effects of antibody, drug and linker on
preclinical and clinical toxicities of ADCs
full text: Europe PMC
* Denintuzumab Mafodotin
(SGN-CD19A antibody-drug conjugate)

Report on Phase 1 safety:
* ASCO Post:
Inotuzumab Ozogamicin (drug-antibody conjugate) Plus Low-Intensity Chemo: A Winner in Older Patients With Leukemia

Comment: IO is drug bound to an antibody a conjugate. The conjugated antibody binds to cd22 on normal and malignant b-cells. When it binds to cd22 the drug attached to the antibody is internalized into the cells leading to cell damage and apoptosis.

Of interest to me is the idea of combining this with lower doses of standard drugs to potentially reduce toxicity and improve efficacy. 

The optimal value of an agent can be hard to estimate when tested as a single agent. As with Rituxan, the potential is also based on how readily it can be combined with other effective agents (without overlapping toxicity and with a mechanism that is complementary and not redundant). In this example, IO given with lower doses of chemotherapy agents improved efficacy and reduced toxicity. What we want and need!

PAL query:
inotuzumab ozogamicin trials for lymphoma

Measuring our impact and interest in this agent:
so far there have been 216 clicks on this query. See )
*Onclive 2014:
Experts discuss Novel ADCs in Development for Lymphoid Malignancies
* Haematologica 2013
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.

* MNT 2013:
Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair
* Brentuximab Vedotin Shows Activity in B-Cell Lymphomas
* Medical Xpress 2013:
Drug-antibody pair has promising activity in non-Hodgkin lymphoma
* ASH Paper, 2013: Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm
* Paper: FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma
* ASH Paper: [Rare] Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event
* Dana Farber 2013:
Drug-antibody pair has promising activity in non-Hodgkin lymphoma


Brentuximab Vedotin (Adcetris)

Brentuximab vedotin has been approved for treatment of relapsed or refractory Hodgkin lymphoma and anaplastic T cell lymphoma.  The trade name is Adcetris.

Adcetris is a antibody-drug conjugate that binds to a molecule called cd30 on cells in Hodgkin lymphoma and anaplastic T cell lymphoma - but also other types of lymphoma at different frequencies or densities.

This targeted antibody is linked to a potent toxin, which is released inside the cell the antibody sticks to.


Full prescribing information (Label):
Brentuximab Vedotin Shows Activity in B-Cell Lymphomas


Disclaimer:  The information on is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns, you should always consult your doctor. 
Copyright 2004,  All Rights Reserved.